Parham Academy LLC
Global learning systems in Science and Medicine


Advertisment




Our news & hot issues


ISI Impact factor= 5.49 (Q1)


Welcome to Parham Academy | Brief discription about the founder


Parham Jabbarzadeh Kaboli, PhD (in progress) in brief:

- A research leader in cancer discovery and cell signaling
- An experienced lecturer in cell and molecular biology
- An young investigator member of the European Association of Cancer Research (EACR)
- An associate member of the American Association of Cancer Research (AACR)
- A member of the American Society for Pharmacology and Experimental Therapeutics (ASPET)
- A member of the American Association for Advancement of Science (AAAS)

►Cellular & molecular pharmacologist
►Research scientist
►Expert in: Cell therapy/drug discovery/Data science
►Problem solver

Parham Jabbarzadeh Kaboli in detailed:

► CAREER PROFILE

• University Lecturer with management experience and exceptional people skills.
• Versed in laboratory tests and bioinformatics with focus on cell biology and cell-based assays.
• Desires a challenging role as a research scientist involving in drug discovery.
• Sale manager in pharmaceutical industry with background as reseller and consultant looking to join a growing entrepreneurial organization as part of the R&D team.

► PHD PROFILE

• Establishment of a virtual high-throughput screening platform to find out more suitable compounds compared with berberine which led to ONE innovation, SIX journal papers, ONE silver medal, and ONE governmental grant ($25000).
• Leading a team to develop virtual high-throughput screening platform (algorithm) by which thousands compounds can be automatically modeled against a specific target, and eventually binding efficiency index and ADMET parameters are predicted.

► COMMUNICATION

• Presenting research results at international scientific meetings in the UK and Italy held by British, European, and American associations for cancer research - BACR, EACR, and AACR respectively.
• Preparing PhD thesis (45,000 words) and annual progress report for grant awarding bodies.
• Teaching and demonstrating at undergraduate practical and tutorial sessions (2000-2013) and online training workshops (2011- present).
• NINE journal papers, FOUR conference papers, and TWO books have been authored which will be available upon request.

► INTERPERSONAL SKILLS

• Collaborating with colleagues to schedule and manage their needs in laboratories, and keeping in touch with suppliers.
• Supporting the development of new colleagues/lecturers through assisting with their professional training to ensure competence and personal safety.
• Recruiting and interviewing with new lecturers (2006-2013).

► CONTACT

parham@gromacs.net



Each weekend, you are linked to the best article that , during each week, I have read and found it great in the field of Cancer and Pharmacology. I try to encourage the fellow researchers and post-graduate students to read so much as they can about new therapeutics.
-------------------------------------------

Weekend Recipe for February 2016 - the fourth week

The birth of modern chemotherapy

This paper published in the Pharmacologist is very interesting showing you how chemotherapy has been evolved as a tool to treat cancer.


Download this recipe

To download other weekend recipes click here.
Author watson Home 15:56:31 | | | printer friendly | | create pdf of this news item



Each weekend, you are linked to the best article that , during each week, I have read and found it great in the field of Cancer and Pharmacology. I try to encourage the fellow researchers and post-graduate students to read so much as they can about new therapeutics.
-------------------------------------------

Weekend Recipe for February 2016 - the second week

The impact of molecular dynamics on drug design: applications for the characterization of ligand– macromolecule complexes

This week I would like to suggest this paper. This paper is very great review paper which is useful for those are interested in drug discovery and are got a little bit confused.

Abstract——Among all tools available to design new drugs, molecular dynamics (MD) simulations have become an essential technique. Initially developed to investigate molecular models with a limited number of atoms, computers now enable investigations of large macromolecular systems with a simulation time reaching the microsecond range.

The reviewed articles cover four years of research to give an overview on the actual impact of MD on the current medicinal chemistry landscape with a particular emphasis on studies of ligand–protein interactions. With a special focus on studies combining computational approaches with data gained from other techniques, this review shows how deeply embedded MD simulations are in drug design strategies and articulates what the future of this technique could be.


Download this recipe

If interested in the field of drug discovery I would also like to suggest these articles. These are well-written too.

To download other weekend recipes click here.

Author watson Home 07:53:45 | | | printer friendly | | create pdf of this news item



Each weekend, you are linked to the best article that , during each week, I have read and found it great in the field of Cancer and Pharmacology. I try to encourage the fellow researchers and post-graduate students to read so much as they can about new therapeutics.
-------------------------------------------

Weekend Recipe for February 2016 - the first week

Ligand efficiency indices for effective drug discovery

This week I would like to suggest this paper. This paper written by Prof. Cele Abad-Zapatero help me a lot to make new insights in drug discovery in my projects. The paper is incredibly insightful and provide new indices to better understanding of drug/target interaction.

Abstract——Successful drug discovery requires the optimization of a large number of variables ranging from strictly physicochemical parameters such as molecular weight to more complex parameters related to toxicity and bioavailability. Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclinical characterization. However, critical biological issues along the path to the market have diminished the impact and power of this methodology. The physicochemical properties of the novel chemical entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate. The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.

More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context. Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.


Download this recipe

To download other weekend recipes click here.
Author watson Home 21:38:55 | | | printer friendly | | create pdf of this news item



One of the objectives of this manuscript is studying of BRAF-MEK interaction.

Water systems were generated so that each docked protein was placed in the center of a triclinic box with the minimum distance between the solutes and the edge of the box of 1.0 nm. The size of the system is 286000 atoms. This system is a huge system and took one month for simulation.

BRAF-MEK1 complex docked by four molecules of BBR-9 can be seen here. Here, we have four BRAFs, four MEK1s, and four ligands. We have done MD to see whether BBR-9 affect BRAF-MEK1 interactions or not.

BBR-9 is one of our newly generated ligands against BRAF. I will also show that BBR-9 is a dual RAF inhibitor because it could affect CRAF as well.

After publication, article and all related supplimentary files will be available here.

RAF-MEK1

Author watson Home 13:04:10 | | | printer friendly | | create pdf of this news item


Go to page  1 2 3
Archives

Selected journal articles watson @ (11:59:34) (Curriculum Vitae)
بسته آمادگی کارشناسی ارشد - صد ساعت watson @ (12:03:46) (کارگاه ها و دوره های حرفه ای)
مدرسه پیشرفته مقاله نویسی watson @ (12:01:41) (کارگاه ها و دوره های حرفه ای)
طراحی دارو و تکنولوژی دراگ دیسکاوری watson @ (12:01:08) (کارگاه ها و دوره های حرفه ای)
Data Science in Genomic Studies watson @ (12:00:31) (کارگاه ها و دوره های حرفه ای)


Our article: Therapeutic miRNAs


 Pharmacological Research




Headlines





Date published: not known
Details

»When you don't want things to stick
»The circuits of itching and scratching
»Sequencing each cell of the nematode
»Unusual star may be supernova debris
»Identification of a new injection system
»A new therapeutic target in view?
»Modeling a pregnancy disorder
»Treating a tumor to metastasize
»Sharing data, protecting privacy
»Collaborative governance


Date published: not known
Details

»A Chinese Perspective on Receptors and Receptor Regulation [Commentary-Molecular Pharmacology in China]
A receptor is a protein molecule that receives chemical signals from outside a cell, which enables ...
»Progress in Pharmacological Sciences in China [Minireview-Molecular Pharmacology in China]
Pharmacology is the science that investigates the interactions between organisms and drugs and thei ...
»The Ca2+-Permeable Cation Transient Receptor Potential TRPV3 Channel: An Emerging Pivotal Target for Itch and Skin Diseases [Minireview-Molecular Pharmacology in China]
Temperature-sensitive transient receptor potential (TRP) channels such as TRPA1 and TRPV1 have been ...
»Phosphorylation of G Protein-Coupled Receptors: From the Barcode Hypothesis to the Flute Model [Minireview-Molecular Pharmacology in China]
Seven transmembrane G protein-coupled receptors (GPCRs) are often phosphorylated at the C terminus ...
»MG53: Biological Function and Potential as a Therapeutic Target [Minireview-Molecular Pharmacology in China]
MG53 (also known as tripartite motif, TRIM72) is a cardiac and skeletal muscle-specific TRIM-family ...
»Tumor Microenvironment Targeting and Responsive Peptide-Based Nanoformulations for Improved Tumor Therapy [Minireview-Molecular Pharmacology in China]
The tumor microenvironment participates in all stages of tumor progression and has emerged as a pro ...
»Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives [Minireview-Molecular Pharmacology in China]
Screening for circulating tumor cells (CTCs) has been identified as one approach to ultrasensitive ...
»The Emerging Role of Cables1 in Cancer and Other Diseases [Minireview-Molecular Pharmacology in China]
Cdk5 and Abl enzyme substrate 1 (Cables1) is an adaptor protein that links cyclin-dependent kinase ...
»Advances in Hypoxia-Mediated Mechanisms in Hepatocellular Carcinoma [Minireview-Molecular Pharmacology in China]
Hepatocellular carcinoma (HCC) is the fifth most common and the third most deadly malignant tumor w ...
»Statins Attenuate Activation of the NLRP3 Inflammasome by Oxidized LDL or TNF{alpha} in Vascular Endothelial Cells through a PXR-Dependent Mechanism [Molecular Pharmacology in China]
Excessive activation of the NLRP3 inflammasome is implicated in cardiovascular diseases. Statins ex ...


Date published: not known
Details

»Limb-Enhancer Genie: An accessible resource of accurate enhancer predictions in the developing limb
»Polymodal allosteric regulation of Type 1 Serine/Threonine Kinase Receptors via a conserved electrostatic lock
»Host population structure impedes reversion to drug sensitivity after discontinuation of treatment
»Spatial dynamics of synthetic microbial mutualists and their parasites
»Neuron’s eye view: Inferring features of complex stimuli from neural responses
»Multidomain analyses of a longitudinal human microbiome intestinal cleanout perturbation experiment
»Efficient and accurate causal inference with hidden confounders from genome-transcriptome variation data
»Extracting replicable associations across multiple studies: Empirical Bayes algorithms for controlling the false discovery rate
»Ten simple rules to initiate and run a postdoctoral association
»Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach
»An optimal strategy for epilepsy surgery: Disruption of the rich-club?
»The application of project-based learning in bioinformatics training


Date published: not known
Details


THE FOUNDER and CEO

Parham Jabbarzadeh Kaboli, PhD

Research scientist
in molecular medicine


Expert in:

Cell and molecular Biology
Modelling and drug discovery
Cancer signaling pathways

H-index= 3 (Google Scholar)
i10-index= 3
Overall ISI impact factor= 18.15
Overall citation= 110 (Google Scholar)

Memberships:

The American Society for Pharmacology and Experimental Therapeutics (ASPET)

American Association for Cancer Research (AACR)

European Association for Cancer Research (EACR)

American Association for Advancement of Science (AAAS)



CONTACT INFORMATION


Affiliation:
Department of Biomedical Science,
Faculty of Medicine and Health Sciences,
Universiti Putra Malaysia,
UPM Serdang 43400,
Selangor, Malaysia

E-Mail: parham@gromacs.net
Telegram: telegram.me/parhamacademy
Featured Publication





View the full list.
Personally Subscribed Journals




Archives

Welcome

Username:

Password:



[ ]







This site is powered by Parham Academy.
This site is powered by Parham Academy.
Render time: 0.1056 sec, 0.0518 of that for queries.